Different micro-RNA expression profiles distinguish subtypes of neuroendocrine tumors of the lung: Results of a profiling study

Modern Pathology

Volumn 27, Issue 12, 2014, Pages 1632-1640

  Mairinger, Fabian Dominik ^a   Ting, Saskia ^a   Werner, Robert ^a   Walter, Robert Fred Henry ^a   Hager, Thomas ^a   Vollbrecht, Claudia ^b   Christoph, Daniel ^a   Worm, Karl ^a   Mairinger, Thomas ^c   Sheu Grabellus, Sien Yi ^a   Theegarten, Dirk ^a   Schmid, Kurt Werner ^a   Wohlschlaeger, Jeremias ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c HELIOS KLINIKUM EMIL VON BEHRING   (Germany)

Author keywords

lung cancer; miR 29; miRNA; neuroendocrine; quantitative real time PCR

Indexed keywords

LET 7D; MICRORNA; MICRORNA 107; MICRORNA 1200; MICRORNA 1201; MICRORNA 125B; MICRORNA 127; MICRORNA 1286; MICRORNA 129; MICRORNA 130B; MICRORNA 132; MICRORNA 136; MICRORNA 143; MICRORNA 154; MICRORNA 15B; MICRORNA 18A; MICRORNA 19; MICRORNA 22; MICRORNA 27B; MICRORNA 29; MICRORNA 29A; MICRORNA 29B; MICRORNA 29C; MICRORNA 31; MICRORNA 335; MICRORNA 340; MICRORNA 367; MICRORNA 504; MICRORNA 513C; MICRORNA 576 5P; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; CELL CYCLE REGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA REPAIR; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; IMMUNE RESPONSE; LUNG TUMOR; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; UPREGULATION; WNT SIGNALING PATHWAY; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; MORTALITY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION;

GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MICRORNAS; NEUROENDOCRINE TUMORS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL;

EID: 84927177916     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2014.74     Document Type: Article

References (57)

1. Guan P, Yin Z, Li X, et al. Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. J Exp Clin Cancer Res 2012;31:54.
2. Ma L, Huang Y, Zhu W, et al. An integrated analysis of miRNA and mRNA expressions in non-small cell lung cancers. PloS one 2011;6:e26502.
3. Lee HW, Lee EH, Ha SY, et al. Altered expression of microRNA miR-21, miR-155, and let-7a and their roles in pulmonary neuroendocrine tumors. Pathol Int. 2012;62:583-591.
4. Travis WD. Lung tumours with neuroendocrine differentiation. Eur J Cancer 2009;45(Suppl 1):251-266.
5. Lee JH, Voortman J, Dingemans AM, et al. MicroRNA expression and clinical outcome of small cell lung cancer. PloS one 2011;6:e21300.
6. Jackman DM, Johnson BE. Small-cell lung cancer. Lancet 2005;366:1385-1396.
7. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-4544.
8. Travis WD, et al. Tumours of the Lung, In: World Health Organization International Histological Classification of Tumours. Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart, 1st edn. IARC Press: Lyon; 2004, pp 9-124.
9. den Bakker MA, Willemsen S, Grunberg K, et al. Small cell carcinoma of the lung and large cell neuroendocrine carcinoma interobserver variability. Histopathology 2010;56:356-363.
10. Travis WD, Gal AA, Colby TV, et al. Reproducibility of neuroendocrine lung tumor classification. Hum Pathol 1998;29:272-279.
11. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-297.
12. Caldas C, Brenton JD. Sizing up miRNAs as cancer genes. Nat Med 2005;11:712-714.
13. Lagos-Quintana M, Rauhut R, Lendeckel W, et al. Identification of novel genes coding for small expressed RNAs. Science 2001;294:853-858.
14. Hutvagner G, Zamore PD. A microRNA in a multipleturnover RNAi enzyme complex. Science 2002;297: 2056-2060.
15. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-866.
16. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009;27: 5848-5856.
17. Cho WC. MicroRNAs in cancer - from research to therapy. Biochim Biophys Acta 2010;1805:209-217.
18. Nunez-Iglesias J, Liu CC, Morgan TE, et al. Joint genome-wide profiling of miRNA and mRNA expression in Alzheimer's disease cortex reveals altered miRNA regulation. PloS one 2010;5:e8898.
19. Clop A. Insights into the importance of miRNA-related polymorphisms to heart disease. Hum Mutat 2009; 30, doi:10.1002/humu.21087.
20. Haramati S, Chapnik E, Sztainberg Y, et al. miRNA malfunction causes spinal motor neuron disease. Proc Natl Acad Sci USA 2010;107:13111-13116.
21. Ruvkun G. Clarifications on miRNA and cancer. Science 2006;311:36-37.
22. Bandres E, Agirre X, Ramirez N, et al. MicroRNAs as cancer players: potential clinical and biological effects. DNA Cell Biol 2007;26:273-282.
23. Sassen S, Miska EA, Caldas C. MicroRNA: implications for cancer. Virchows Arch 2008;452:1-10.
24. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-269.
25. Schmitz KJ, Helwig J, Bertram S, et al. Differential expression of microRNA-675, microRNA-139-3p and microRNA-335 in benign and malignant adrenocortical tumours. J Clin Pathol 2011;64:529-535.
26. Sheu SY, Vogel E, Worm K, et al. Hyalinizing trabecular tumour of the thyroid-differential expression of distinct miRNAs compared with papillary thyroid carcinoma. Histopathology 2010;56:632-640.
27. Sheu SY, Grabellus F, Schwertheim S, et al. Differential miRNA expression profiles in variants of papillary thyroid carcinoma and encapsulated follicular thyroid tumours. Br J Cancer 2010;102:376-382.
28. Schwertheim S, Sheu SY, Worm K, et al. Analysis of deregulated miRNAs is helpful to distinguish poorly differentiated thyroid carcinoma from papillary thyroid carcinoma. Horm Metab Res 2009;41:475-481.
29. Sheu SY, Grabellus F, Schwertheim S, et al. Lack of correlation between BRAF V600E mutational status and the expression profile of a distinct set of miRNAs in papillary thyroid carcinoma. Horm Metab Res 2009;41:482-487.
30. He L, He X, Lim LP, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007;447:1130-1134.
31. Fabbri M, Garzon R, Cimmino A, et al. MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007;104:15805-15810.
32. Plaisier CL, Pan M, Baliga NS. A miRNA-regulatory network explains how dysregulated miRNAs perturb oncogenic processes across diverse cancers. Genome Res 2012;22:2302-2314.
33. Gebeshuber CA, Zatloukal K, Martinez J. miR-29a suppresses tristetraprolin, which is a regulator of epithelial polarity and metastasis. EMBO rep 2009;10:400-405.
34. Balca-Silva J, Sousa Neves S, Goncalves AC, et al. Effect of miR-34b overexpression on the radiosensitivity of non-small cell lung cancer cell lines. Anticancer Res 2012;32:1603-1609.
35. Wang LG, Ni Y, Su BH, et al. MicroRNA-34b functions as a tumor suppressor and acts as a nodal point in the feedback loop with Met. Int J Oncol 2013;42:957-962.
36. Wang Z, Chen Z, Gao Y, et al. DNA hypermethylation of microRNA-34b/c has prognostic value for stage non-small cell lung cancer. Cancer Biol Ther 2011;11: 490-496.
37. Nishikawa E, Osada H, Okazaki Y, et al. miR-375 is activated by ASH1 and inhibits YAP1 in a lineagedependent manner in lung cancer. Cancer Res 2011; 71:6165-6173.
38. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120: 635-647.
39. Yanaihara N, Caplen N, Bowman E, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-198.
40. Yu SL, Chen HY, Chang GC, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008;13:48-57.
41. Markou A, Tsaroucha EG, Kaklamanis L, et al. Prognostic value of mature microRNA-21 and microRNA- 205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 2008;54: 1696-1704.
42. Liu X, Sempere LF, Ouyang H, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 2010;120:1298-1309.
43. Lebanony D, Benjamin H, Gilad S, et al. Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous nonsmall- cell lung carcinoma. J Clin Oncol 2009;27: 2030-2037.
44. Wang XC, Du LQ, Tian LL, et al. Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer. Lung Cancer. 2011;72:92-99.
45. Bustin SA, Benes V, Garson JA, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 2009;55:611-622.
46. Walter RF, Mairinger FD, Wohlschlaeger J, et al. FFPE tissue as a feasible source for gene expression analysis - a comparison of three reference genes and one tumor marker. Pathol Res Pract 2013;209:784-789.
47. Peiro-Chova L, Pena-Chilet M, Lopez-Guerrero JA, et al. High stability of microRNAs in tissue samples of compromised quality. Virchows Arch 2013;463: 765-774.
48. Park SY, Lee JH, Ha M, et al. miR-29 miRNAs activate p53 by targeting p85 alpha and CDC42. Nat Struct Mol Biol 2009;16:23-29.
49. Cingarlini S, Bonomi M, Corbo V, et al. Profiling mTOR pathway in neuroendocrine tumors. Target Oncol 2012;7:183-188.
50. Fang R, Xiao T, Fang Z, et al. MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene. J Biol Chem 2012;287:23227-23235.
51. Osada H, Tomida S, Yatabe Y, et al. Roles of achaetescute homologue 1 in DKK1 and E-cadherin repression and neuroendocrine differentiation in lung cancer. Cancer Res 2008;68:1647-1655.
52. Osada H, Tatematsu Y, Yatabe Y, et al. ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. Cancer Res 2005;65: 10680-10685.
53. Vicent S, Garayoa M, Lopez-Picazo JM, et al. Mitogenactivated protein kinase phosphatase-1 is overexpressed in non-small cell lung cancer and is an independent predictor of outcome in patients. Clin Cancer Res 2004;10:3639-3649.
54. Widmann C, Gibson S, Jarpe MB, et al. Mitogenactivated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 1999;79: 143-180.
55. Blackhall FH, Pintilie M, Michael M, et al. Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res 2003;9: 2241-2247.
56. Su B, Karin M. Mitogen-activated protein kinase cascades and regulation of gene expression. Curr Opin Immunol 1996;8:402-411.
57. Cano E, Mahadevan LC. Parallel signal processing among mammalian MAPKs. Trends Biochem Sci 1995; 20:117-122.